With the release candidate version 2 presented last week, Apple also provided a package insert for the first time. This contains an overview of the new features. It includes some exciting details ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

Libtayo shows robust growth in specific cancers, although it faces stiff competition in broader indications, highlighting Regeneron’s ability to develop blockbuster drugs. Regeneron appears ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.

Despite these challenges, Regeneron's other drugs, particularly Dupixent and Libtayo, show promise for future growth and revenue generation. Given the current uncertainties and risks, I rate ...

Letybo (letibotulinumtoxinA-wlbg) is now available for the temporary improvement in the appearance of moderate to severe glabellar lines.

One patient with Merkel cell carcinoma (MCC) achieved a durable complete response with 15 milligrams per kilogram (mg/kg) solnerstotug and Libtayo (cemiplimab) and remains on treatment at 42 or more ...

PULLMAN – For the second consecutive season, Washington State will likely have to replace its entire men’s basketball starting lineup. Sophomore wing LeJuan Watts is entering the transfer ...

Nearly four in 10 shoppers have had a package stolen. This is according to a study commissioned by ValuePenguin. Although the number of deliveries increases during the holidays, package theft is ...

What is the difference between orthotics, insoles and shoe inserts? According to Scholl, the main difference between insoles and shoe inserts is that the former is a full-sized replacement for the ...

When you buy through our links, we may earn a commission. Before you ask, we haven’t put every beginner package set through full launch monitor testing to see which one flies the farthest. But let’s ...

Panelists discuss how the five-year prognosis for advanced non-small cell lung cancer (NSCLC) has improved with PD-1 inhibitors, showing promising overall survival (OS) and progression-free survival ...